Judge cites Cochrane, dismissing Nurofen's claim to superiority


Advertising claims that Nurofen is better than Panadol for headaches have been struck down by a judge who accepted expert advice that Cochrane reviews take priority over results from individual studies.

In a two-year legal case brought by GlaxoSmithKline (GSK) against Reckitt Benckiser, a judge had to consider what level of scientific evidence was necessary to justify analgesic claims on TV and in print ads in Women’s Health magazine.

The ads claimed Nurofen was superior to Panadol for treating tension-type headaches.